BIOMAT Database Logo BIOMAT Database Logo

Comparative studies of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues. 1990

J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Bristol-Myers Squibb, Wallingford, Connecticut 06492.

UI MeSH Term Description Entries
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857

Related Publications

J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Structural studies of the anti-HIV agent 2',3'-didehydro-2',3'-dideoxythymidine (D4T).
February 1991, Biochemical and biophysical research communications,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Suppression of murine retroviral disease by 2',3'-didehydro-2',3'-dideoxythymidine (D4T).
October 1992, Antiviral research,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells.
May 1990, Biochemical pharmacology,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Measurement of the anti-HIV agent 2',3'-didehydro-2',3'-dideoxythymidine (D4T) by competitive ELISA.
November 1994, Journal of immunological methods,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).
January 1999, Drug metabolism and disposition: the biological fate of chemicals,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).
June 1995, Antiviral research,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine monophosphate: efficient intracellular delivery of d4TMP.
November 2000, Molecular pharmacology,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Synthesis and antiviral evaluation of thieno[3,4-d]pyrimidine C-nucleoside analogues of 2',3'-dideoxy- and 2',3'-dideoxy-2',3'-didehydro-adenosine and -inosine.
March 2009, Bioorganic & medicinal chemistry,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes.
August 1997, Antiviral research,
J C Martin, and M J Hitchcock, and A Fridland, and I Ghazzouli, and S Kaul, and L M Dunkle, and R Z Sterzycki, and M M Mansuri
Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma.
June 1996, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!